(―)-Epiafzelechin protects against ovariectomy-induced bone loss in adult mice and modulate osteoblastic and osteoclastic functions in vitro

Ka Chun Wong, Sisi Cao, Xiaoli Dong, Man Chun Law, Tak Hang Chan, Man Sau Wong

Research output: Journal article publicationJournal articleAcademic researchpeer-review

8 Citations (Scopus)


Licensee MDPI, Basel, Switzerland. The present study was designed to characterize the bone protective effects of (―)-epiafzelechin (EAF), a flavan-3-ol, in mature ovariectomized mice model and its ability to stimulate osteoblastic activity and inhibit osteoclastic activity. Mature C57BL/6 mice (three to four months old) were either ovariectomised (OVX) or sham-operated and subjected to treatment (vehicle, 17β-oestradiol (E2, 200 μg/kg/day) or EAF (500 μg/kg/day) orally for six weeks. EAF and E2 significantly reduced urinary calcium (Ca) excretion, serum osteocalcin (OCN), and urinary deoxy-pyridinoline (DPD); increased bone mineral density (BMD); and improved micro-architectural properties in OVX mice. EAF significantly increased cell viability, alkaline phosphatise (ALP) activity, and collagen content, as well as runt-related transcriptional factor 2 (Runx2) mRNA expression in murine osteoblastic MC3T3-E1 cells. In addition, EAF significantly reduced the viability of osteoclast precursor murine leukemia monocyte RAW264.7 cells and tartrate-resistant acid phosphatase (TRAP) activities in mature osteoclastic RAW 264.7 cells. EAF is a bioactive flavan-3-ol that protects estrogen deficiency-induced bone loss in OVX mice and exerts direct modulating effects in bone cells in vitro.
Original languageEnglish
Article number530
Issue number5
Publication statusPublished - 22 May 2017


  • (―)-epiafzelechin
  • Flavan-3-ol
  • Osteoclastogenesis
  • Osteogenesis
  • Ovariectomised
  • Trabecular bone

ASJC Scopus subject areas

  • Food Science
  • Nutrition and Dietetics

Cite this